Advances in traditional Chinese medicine treatment of primary biliary cholangitis-related liver fibrosis
- VernacularTitle:原发性胆汁性胆管炎相关肝纤维化中医药治疗进展
- Author:
Chenyang ZHANG
1
;
Wei ZHANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Primary Biliary Cholangitis; Hepatic Fibrosis; Anti-Hepato Fibrosis Agents （TCD）; Therapeutics
- From: Journal of Clinical Hepatology 2025;41(10):1975-1980
- CountryChina
- Language:Chinese
- Abstract: Primary biliary cholangitis （PBC） is a chronic progressive autoimmune liver disease that often progresses to liver fibrosis and even liver cirrhosis. This article summarizes and reviews the research advances in the combined use of traditional Chinese medicine （TCM） and ursodeoxycholic acid in the treatment of PBC-related liver fibrosis. Various studies have shown that integrated traditional Chinese and Western medicine therapy can improve serum fibrosis markers， noninvasive liver fibrosis scores， and liver stiffness measurement in PBC patients with liver fibrosis， with a relatively good safety profile and a potential to delay or even reverse the progression of PBC-related liver fibrosis. However， current evidence is mainly derived from small-scale or short-term clinical observational studies， and in the future， large-scale high-quality randomized controlled trials and long-term follow-up studies are needed in combination with modern scientific technologies to explore underlying mechanisms， thereby further validating its efficacy and promoting the establishment of an evidence-based precise diagnosis and treatment system based on integrated traditional Chinese and Western medicine therapies. Through in-depth research， TCM is expected to play a more important role in the treatment of PBC-related liver fibrosis.
